DBV Technologies SA (DBV) has drawn suitors after its peanut allergy patch showed positive results in early tests. The company is spurning advances because it wants to go it alone.
Boosted by a study that showed its Viaskin patch allowed about half of children with the affliction to tolerate more peanuts, the French company’s stock has almost quadrupled this year, for a market value close to $1 billion. DBV raised about $100 million selling shares in the U.S. in October, letting it turn away approaches from bigger companies as it performs trials.
Help employers find you! Check out all the jobs and post your resume.
